Key result
Gatifloxacin exposure in patients on stable warfarin therapy was associated with a significantly higher rate of an INR above 4 compared with levofloxacin (21% vs 2%, p=0.003).
Why the study?
Does gatifloxacin compared to levofloxacin increase the risk of supratherapeutic INR and related adverse events in patients on stable warfarin?
Cohort (n=92)
No
Does gatifloxacin compared to levofloxacin increase the risk of supratherapeutic INR and related adverse events in patients on stable warfarin?
Gatifloxacin is associated with a significantly higher risk of supratherapeutic INR and need for vitamin K compared to levofloxacin in patients on stable warfarin therapy.
Answers are grounded in this paper and cite their sources.
May warrant INR monitoring with gatifloxacin in warfarin patients; leaves open confirmation of bleeding risk in randomized trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Mathews et al. (2006) conducted a cohort in Patients on stable warfarin therapy requiring fluoroquinolones (n=92). Gatifloxacin vs. Levofloxacin was evaluated on Postfluoroquinolone INR above 4 (p=0.003). Gatifloxacin exposure in patients on stable warfarin therapy was associated with a significantly higher rate of an INR above 4 compared with levofloxacin (21% vs 2%, p=0.003).
Synapse has enriched 10 related papers. Consider them for comparative context: